Atlas Trials

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting

Clinical trial NCT03159403 · COMPLETED

Trial details

NCT number
NCT03159403
Sponsor
Melinta Therapeutics, Inc.
Status
COMPLETED
Study type
OBSERVATIONAL
Gram-Positive Bacterial Infections
Start date
2017-04-12
Primary completion
2018-02-15
Enrollment
325

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.